150 related articles for article (PubMed ID: 1912555)
1. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a.
Smith JW; Longo DL; Urba WJ; Clark JW; Watson T; Beveridge J; Conlon KC; Sznol M; Creekmore SP; Alvord WG
Blood; 1991 Oct; 78(7):1664-71. PubMed ID: 1912555
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b.
Glaspy JA; Souza L; Scates S; Narachi M; Blatt L; Ambersley J; Golde DW
J Immunother (1991); 1992 Apr; 11(3):198-208. PubMed ID: 1381218
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL.
Federico M; Frassoldati A; Lamparelli T; Foà R; Brugiatelli M; Annino L; Baldini L; Capnist G; Chisesi T; di Celle PF
Ann Oncol; 1994 Oct; 5(8):725-31. PubMed ID: 7826905
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study.
Martin A; Nerenstone S; Urba WJ; Longo DL; Lawrence JB; Clark JW; Hawkins MJ; Creekmore SP; Smith JW; Steis RG
J Clin Oncol; 1990 Apr; 8(4):721-30. PubMed ID: 2313337
[TBL] [Abstract][Full Text] [Related]
5. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a.
Berman E; Heller G; Kempin S; Gee T; Tran LL; Clarkson B
Blood; 1990 Feb; 75(4):839-45. PubMed ID: 2302457
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interferon-alpha-2b treatment of hairy-cell leukaemia: experience with a low-dose schedule.
Hasselbalch H; Braide I; Lisse I; Röckert LL; Swolin B; Carneskog J; Hagberg H; Hippe E; Jensen MK; Lundin P
Eur J Haematol; 1988 Nov; 41(5):438-44. PubMed ID: 3061836
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment.
Lauria F; Rondelli D; Raspadori D; Zinzani PL; Benfenati D; Pileri S; Sabattini E; Tura S
Leuk Lymphoma; 1992 May; 7(1-2):103-7. PubMed ID: 1472920
[TBL] [Abstract][Full Text] [Related]
8. A randomized comparison of two doses of human lymphoblastoid interferon-alpha in hairy cell leukemia. Wellcome HCL Study Group.
Smalley RV; Anderson SA; Tuttle RL; Connors J; Thurmond LM; Huang A; Castle K; Magers C; Whisnant JK
Blood; 1991 Dec; 78(12):3133-41. PubMed ID: 1742480
[TBL] [Abstract][Full Text] [Related]
9. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia.
Habermann TM; Andersen JW; Cassileth PA; Bennett JM; Oken MM
Br J Haematol; 1992 Apr; 80(4):466-71. PubMed ID: 1581231
[TBL] [Abstract][Full Text] [Related]
10. Long term results of interferon treatment in hairy cell leukemia. Italian Cooperative Group of Hairy Cell Leukemia (ICGHCL).
Capnist G; Federico M; Chisesi T; Resegotti L; Lamparelli T; Fabris P; Rossi G; Invernizzi R; Guarnaccia C; Leoni P
Leuk Lymphoma; 1994 Aug; 14(5-6):457-64. PubMed ID: 7812205
[TBL] [Abstract][Full Text] [Related]
11. Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.
Moormeier JA; Ratain MJ; Westbrook CA; Vardiman JW; Daly KM; Golomb HM
J Natl Cancer Inst; 1989 Aug; 81(15):1172-4. PubMed ID: 2746669
[TBL] [Abstract][Full Text] [Related]
12. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.
Golomb HM; Jacobs A; Fefer A; Ozer H; Thompson J; Portlock C; Ratain M; Golde D; Vardiman J; Burke JS
J Clin Oncol; 1986 Jun; 4(6):900-5. PubMed ID: 3519880
[TBL] [Abstract][Full Text] [Related]
13. Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia.
von Wussow P; Pralle H; Hochkeppel HK; Jakschies D; Sonnen S; Schmidt H; Müller-Rosenau D; Franke M; Haferlach T; Zwingers T
Blood; 1991 Jul; 78(1):38-43. PubMed ID: 2070058
[TBL] [Abstract][Full Text] [Related]
14. Three years' continuous low-dose interferon-alpha treatment of hairy-cell leukaemia: evaluation of response and maintenance dose.
Nielsen B; Braide I
Eur J Haematol; 1992 Oct; 49(4):174-9. PubMed ID: 1343089
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
Anger B; Porzsolt F; Leichtle R; Heinze B; Bartram C; Heimpel H
Blut; 1989 Jun; 58(6):275-8. PubMed ID: 2736308
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hairy cell leukemia with increasing doses of recombinant alpha A interferon.
Holmes R; Schwarz MA; Whiteside MG; Firkin FC
Aust N Z J Med; 1988 Jun; 18(4):557-62. PubMed ID: 3196242
[TBL] [Abstract][Full Text] [Related]
17. The alpha 2 (r) interferon in the treatment of hairy cell leukemia: progressive report of 25 cases.
Mandelli F; Cafolla A; Annino L; Amadori S; Gentile A; Bianco P; Dianzani F
J Biol Regul Homeost Agents; 1987; 1(4):177-82. PubMed ID: 3332545
[TBL] [Abstract][Full Text] [Related]
18. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera.
Foa P; Massaro P; Caldiera S; LaTargia ML; Iurlo A; Clerici C; Fornier M; Bertoni F; Maiolo AT
Eur J Haematol; 1998 May; 60(5):273-7. PubMed ID: 9654155
[TBL] [Abstract][Full Text] [Related]
19. Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.
Golomb HM; Fefer A; Golde DW; Ozer H; Portlock C; Silber R; Rappeport J; Ratain MJ; Thompson J; Bonnem EM
Semin Oncol; 1987 Jun; 14(2 Suppl 2):13-7. PubMed ID: 3589701
[TBL] [Abstract][Full Text] [Related]
20. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
